… Lung cancer is the leading cause of cancer related deaths worldwide, and non-small cell
lung cancer (NSCLC) accounts for about 85% of overall reported cases.A clinically significant …

… efficacy with ALK inhibitors, including alectinib.3, 8 Here we report updated efficacy and safety
… 1, 2017) and an exploratory analysis of efficacy by EML4-ALK fusion variant. We discuss …

… Lung cancer remains the leading cause of cancer-related morbidity and mortality worldwide
1 . Non-small-cell lung cancer (… as having advanced or metastatic lung cancer at the time of …

… of first-line (1L) therapy for advanced non-small cell cancer (NSCLC). The objective of this
study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of …

… Small-cell lung cancer (SCLC) accounts for approximately 13% to 15% of all lung cancers
with an estimate of more than 180,000 new cases diagnosed annually worldwide (1–3). This …

… Lung cancer remains the leading cause of cancer-associated deaths globally. Non-small
cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [1] and …

… Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-…
About 80%–85% of patients have non-small cell lung cancers (NSCLC), and most have locally …

Background For patients (pts) with resected, stage IB–IIIA, ALK+ NSCLC, the recommended
treatment after surgery is platinum-based chemotherapy (CT), which is associated with …

… Lung cancer remains the leading global cause of cancer-… cell lung cancer (NSCLC) accounts
for 85% of all lung cancers … is safe and effective for treating advanced squamous cell lung …

Importance Because of socioeconomic factors, many patients with advanced non–small cell
lung cancer (NSCLC) do not receive immunotherapy in the first-line setting. It is unknown if …